Get started
Author

Miguel Esperança‐Martins

Observed names: M Esperança-Martins, M. Esperanca-Martins, M. Esperança-Martins, Miguel Esperanca-Martins, Miguel Esperança-Martins, Miguel Esperança‑Martins
Observed institutions: University of Lisbon, Unidade Local de Saúde de Entre Douro e Vouga, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Instituto de Medicina Molecular João Lobo Antunes, Hospital CUF Descobertas, Gulbenkian Institute for Molecular Medicine, Unidade Local de Saúde Santa Maria, Comprehensive Health Research Centre, Universidade Nova de Lisboa
ORCID: 0000-0002-6858-7341
Observed ORCID: 0000-0002-6858-7341
OpenAlex ID: A5023653574
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
2024 · Clara Oliveira, Beatrice Mainoli, et al. · European Journal of Clinical Pharmacology · 58
PDF
Multidisciplinary Approach to Spinal Metastases and Metastatic Spinal Cord Compression—A New Integrative Flowchart for Patient Management
2023 · Miguel Esperança-Martins, Diogo Roque, et al. · Cancers · 49
PDF
Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
2023 · Lisa Gonçalves, Duarte Gonçalves, et al. · Cells · 39
PDF
Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
2021 · Isabel Fernandes, Cecília Melo-Alvim, et al. · International Journal of Molecular Sciences · 35
PDF
Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Turning the Magnifying Glass on Rare and Aggressive Entities
2023 · Miguel Esperança-Martins, Cecília Melo-Alvim, et al. · Cancers · 19
PDF
Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal
2022 · Raquel Lopes-Brás, Dolores Lopez-Presa, et al. · International Journal of Molecular Sciences · 19
PDF
Sarcoma Metabolomics: Current Horizons and Future Perspectives
2021 · Miguel Esperança-Martins, Isabel Fernandes, et al. · Cells · 19
PDF
Humoral Immune Response of SARS-CoV -2–Infected Patients with Cancer: Influencing Factors and Mechanisms
2021 · Miguel Esperança-Martins, Lisa Gonçalves, et al. · The Oncologist · 15
PDF
Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study
2025 · Paulo Luz, Raquel Lopes-Brás, et al. · Clinical & Translational Oncology · 11
PDF
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
2023 · Inês Soares de Pinho, Paulo Luz, et al. · Clinical Drug Investigation · 9
PDF
Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives
2022 · Joaquim Soares do Brito, Miguel Esperança-Martins, et al. · Cancers · 8
PDF
Vasculitis and Breast Cancer: Mind the Hint
2021 · Miguel Esperança-Martins, Vasco Evangelista, et al. · Case Reports in Oncology · 7
PDF
Retro TIMing: A multicentric retrospective analysis of immunotherapy timing in metastatic melanoma.
2024 · Lisa Gonçalves, Duarte Goncalves, et al. · Journal of Clinical Oncology · 6
PDF
Transcriptomic-Based Classification Identifies Prognostic Subtypes and Therapeutic Strategies in Soft Tissue Sarcomas
2025 · Miguel Esperança-Martins, Hugo Vasques, et al. · Cancers · 5
PDF
Succinate Dehydrogenase B (SDHB) Overexpression with Enzymatic Dysfunction Defines a Distinct Subtype of Undifferentiated Pleomorphic Sarcoma
2025 · Miguel Esperança-Martins, Hugo Vasques, et al. · Cancer Research Communications · 4
PDF
Ibero-American Consensus for the Management of Liver Metastases of Soft Tissue Sarcoma: Updated Review and Clinical Recommendations
2025 · Raquel Lopes-Brás, Paula Muñoz, et al. · Cancers · 4
PDF
Correction to: Immune‑related serious adverse events with immune checkpoint inhibitors: systematic review and network meta‑analysis
2024 · Clara Oliveira, Beatrice Mainoli, et al. · European Journal of Clinical Pharmacology · 4
On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping
2022 · Miguel Esperança-Martins, Iola F.Duarte, et al. · International Journal of Molecular Sciences · 3
PDF
Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment
2022 · Sara Dâmaso, Rita Paiva, et al. · memo - Magazine of European Medical Oncology · 2
Immunotherapy in Soft Tissue Sarcomas—An Ongoing Quest
2026 · Silvana Cobeña, Miguel Esperança-Martins, et al. · Cells · 1
CDK4/6 Inhibitors-Induced Macrocytosis Is Not Associated with Hemolysis and Does Not Impact Hemoglobin Homeostasis
2025 · Tiago Barroso, Leila Costa, et al. · Cancers · 1
PDF
Machine learning-based analysis of genomic and transcriptomic data unveils sarcoma clusters with superlative prognostic and predictive value
2025 · Miguel Esperança-Martins, Hugo Vasques, et al. · medRxiv · 1
PDF
Immune Thrombocytopenic Purpura and Ganglionic Tuberculosis: An Unlikely Link
2024 · Henrique Atalaia Barbacena, Miguel Esperança-Martins, et al. · Cureus · 1
PDF
P11.54.a Brain Relapse in Her2-positive Breast Cancer After Neoadjuvant Treatment: an International Multicentric Study
2023 · A Fortuna, A Nobre Carvalho, et al. · Neuro-Oncology · 1
PDF
Genomic foundation models extend clinicopathologic and transcriptomic prognostication in soft tissue sarcoma
2026 · Miguel Esperança-Martins, Manuel Sokolov Ravasqueira, et al. · medRxiv
PDF
Works count: 84
Citation count: 321
H-index: 9
I10-index: 9
Year
Topic
Type